Abstract 3845
Background
For colorectal liver metastases (CRLM), some key prognostic factors— KRAS/NRAS/BRAF, location of primary tumor, and CA19-9—were identified for recurrence and survival but were rarely included in prognostic scoring system analysis. Besides, tumor burden score (TBS) is a prognostic indicator capturing the cumulative impact CRLM size and CRLM number, but TBS does not take spatial factor—unilobar or bilobar metastasis—into account.
Methods
787 patients undergoing hepatic resection of CRLM were included and were divided into training and validation groups. Modified TBS (mTBS) was established by a mathematical equation (parameters were CRLM size, CRLM number, and unilobar/bilobar metastasis). In the training group, the Cox proportional hazards model was used to identify independent predictors of prognosis; these factors were combined into the Comprehensive Evaluation of Recurrence Risk (CERR) score. The score was compared with Fong score and “Genetic and Morphological Evaluation” (GAME) score and validated in the validation group. Some indices (including C-index, iAUC, Akaike information criterion, net reclassification index, and integrated discrimination improvement) were calculated to compare the discriminatory capacities of three prognostic scoring systems.
Results
mTBS (AUC 0.617) out-performed TBS (AUC 0.568) in predicting recurrence-free survival (RFS) (P = 0.006). Five preoperative predictors of worse RFS were identified and were incorporated into CERR score: KRAS/NRAS/BRAF mutated tumor (1 point); node-positive primary (1 point); extrahepatic disease (1 point); CEA >200 ng/ml or CA19-9 >200 U/mL (1 point); mTBS between 5 and 11 (1 point) or 12 and over (2 points). Patients undergoing hepatectomy for CRLM were stratified by CERR score into risk groups: high-risk group (CERR score 4 or more) had a 3-year RFS rate of 9.77%; medium-risk group (CERR score 2-3) had a 3-year RFS rate of 21.96%; low-risk group (CERR score 0-1) had a 3-year RFS rate of 39.90%. The validation group showed that the discriminatory capacity of the CERR score was superior to that of the Fong score and the GAME score.
Conclusions
The CERR score is a prognostic tool that can be used to determine optimal clinical management strategies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Zhongshan Hospital, Fudan University, Shanghai, China.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3516 - Palbociclib Rechallenge in Hormone Receptor (HR)[+]/HER2[-] Advanced Breast Cancer (ABC). PALMIRA Trial
Presenter: Antonio Llombart Cussac
Session: Poster Display session 2
Resources:
Abstract
4616 - Alpelisib (ALP) + Endocrine Therapy (ET) by Last Prior Therapy in Patients (pts) With PIK3CA-Mutated Hormone-Receptor Positive (HR+) Human Epidermal Growth Factor Receptor-2-Negative (HER2–) Advanced Breast Cancer (ABC): Additional Study Cohort in BYLieve
Presenter: Eva Ciruelos
Session: Poster Display session 2
Resources:
Abstract
3592 - PRECYCLE: Impact of CANKADO-based eHealth-support on quality of life in metastatic breast cancer patients treated with palbociclib and endocrine therapy.
Presenter: Tom Degenhardt
Session: Poster Display session 2
Resources:
Abstract
4168 - Efficacy and safety of oral poly (ADP-ribose) polymerase inhibitor fluzoparib in patients with BRCA1/2 mutations and platinum sensitive recurrent ovarian cancer
Presenter: Ning Li
Session: Poster Display session 2
Resources:
Abstract
2785 - Effect of response to last platinum-based chemotherapy in patients (pts) with platinum-sensitive, recurrent ovarian carcinoma in the phase 3 study ARIEL3 of rucaparib maintenance treatment
Presenter: Jonathan Ledermann
Session: Poster Display session 2
Resources:
Abstract
3496 - Integrated safety analysis of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with ovarian cancer in the treatment and maintenance settings
Presenter: Rebecca Kristeleit
Session: Poster Display session 2
Resources:
Abstract
2844 - Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers
Presenter: S.Intidhar Labidi-Galy
Session: Poster Display session 2
Resources:
Abstract
1955 - A Prospective Evaluation of Tolerability of Niraparib Dosing Based on Baseline Body Weight (BW) and Platelet (plt) Count: Blinded Pooled Interim Safety Data from the NORA Study
Presenter: Xiaohua Wu
Session: Poster Display session 2
Resources:
Abstract
2539 - Evaluation of Niraparib 200 mg/d as Maintenance Therapy in Recurrent Ovarian Cancer and Associated Thrombocytopenia in a Real-World US Setting
Presenter: Premal Thaker
Session: Poster Display session 2
Resources:
Abstract
1290 - Niraparib initial dose and its’ management in patients with recurrent high-grade serous ovarian cancer.
Presenter: Jacek Grabowski
Session: Poster Display session 2
Resources:
Abstract